With ever-increasing payer cost controls and complex distribution logistics of novel therapies, Cancer Centers prioritize initiatives to enhance oncology pharmacy revenue, such as contracting and use of cost-effective medications. HIRC's report, Academic Institution & Health System-based Cancer Centers: Market Trends and Manufacturer Competitive Assessment, reviews the market environment for Cancer Centers, their strategic imperatives for 2024, and a competitive assessment of oncology medication manufacturers in Cancer Center engagement. The report addresses the following:

• What are Cancer Centers' top market concerns and strategic priorities in 2024?
• What is the status of Cancer Center activity related to oncology pharmacy and dispensing services (e.g., alternate site infusion, specialty pharmacy)?
• What is the status of oncology preferred drug lists, clinical pathways, and other utilization management tactics?
• What is the status of oncology biosimilar adoption among Cancer Centers?
• Which firms are most often nominated as Cancer Centers' partner of choice? Which firms are nominated as providing the best oncology-related support offerings?
• How do pharmaceutical firms benchmark in account engagement and quality of oncology account managers, medical/clinical science liaisons, and field-based reimbursement managers?

Key Finding: Adequate staffing and training to support expansion/growth, and moving CAR-T cell treatment to an outpatient setting are among Cancer Centers' top strategic priorities for 2024.

Top Market Trends for Cancer Centers in 2024. Cancer Center respondents identify a number of market trends with the potential to impact their organizations, including (1) declining reimbursement from payers (both commercial and government programs), (2) BiTE (bispecific T-cell engager) therapy, (3) oncology biosimilars - opportunities and payer mandates, and (4) payers' site of care programs.

The full report provides the complete listing of 50+ trends identified by Cancer Centers, as well as their top strategic imperatives for the next 12-18 months.

Cancer Centers Most Frequently Designate Preferred Products in Categories with Oncology Biosimilars. About 84% of respondents in HIRC's sample report having preferred oncology biosimilar products in place in 2024, followed by 48% with preferred IV conventional chemotherapies, and 35% with preferred IV targeted therapies. The full report examines biosimilars in detail, including which are preferred and how Cancer Centers promote their use.

Pharmaceutical Manufacturer Competitive Assessment. Cancer Center respondents were asked to evaluate three types of manufacturer customer-facing personnel as noted below. Amgen, Pfizer Oncology, Merck Oncology, and Genentech rate highest in overall manufacturer field personnel engagement. The complete report provides Cancer Center executives' ratings of 26 firms active in the oncology space, as well as ratings of manufacturer's oncology-related support offerings and nominations for overall partner of choice.

Research Methodology and Report Availability. In January HIRC surveyed 31 executives from Cancer Centers. Online surveys and follow-up telephone interviews were used to gather information. The complete report, Academic Institution & Health System-based Cancer Centers: Market Trends and Manufacturer Competitive Assessment, is available now to HIRC’s Managed Oncology subscribers at www.hirc.com.